BlackRock Health Sciences Opportunities Portfolio (BME)
NYSE NYSE Primary NASDAQ (NMS) Summary
BME Chart
B&M shares slide but analysts say quarter changes little
B&M European Value Retail SA (LSE:BME) shares fell after the discount retailer reported a decline in underlying UK sales, although analysts said the update was largely in line with expectations and did little to alter the investment case. Shares in the FTSE 250-listed group fell 5.8% to 192.1p by early afternoon on Wednesday.
B&M reports improved UK trading and strong sales in France
B&M European Value Retail SA (LSE:BME) reported first-quarter sales growth of 2% as strong trading in France and steady growth at Heron Foods helped lift group revenue despite weaker trading in its core UK business. The discount retailer said revenue rose to £1.43 billion in the 13 weeks to 27 June from a year earlier.
Broker puts B&M under review and warns re-rating is unlikely despite shares surging 15.5%
B&M European Value Retail SA (LSE:BME) shares surged 15.5% to 196.9p after full-year results came in line with guidance, but Shore Capital has placed the discount retailer under review and cautioned that the conditions for a meaningful re-rating are not yet in place. The broker, which had previously held a 'buy' rating on the stock, acknowledged that the financial year to March represented progress after what management itself described as a difficult year.
BlackRock Health Sciences Opportunities Portfolio Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RC Robert Chess L.M. Kohn & Company | 5,688 | $231,023.64 | $240,374.88 | $9,351.24 | 4.05% |
 Daniel L. Lippincott Karpus Management Inc. | 141,442 | $5.41M | $5.98M | $563,905.16 | 10.42% |
 Jeff Ameen Spire Wealth Management | 234 | $10,709.86 | $9,947.34 | -$762.52 | -7.12% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 500 | $20,565 | $21,092.5 | $527.5 | 2.57% |
 Michael Byun SageView Advisory Group LLC | 1,010 | $41,541 | $43,187.6 | $1,646.6 | 3.96% |
BlackRock Health Sciences Opportunities Portfolio (BME) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BlackRock Health Sciences Opportunities Portfolio ever had a stock split?
BlackRock Health Sciences Opportunities Portfolio Profile
| NYSE Exchange | US Country |
Overview
The BlackRock Health Sciences Trust is a standout closed-end equity mutual fund that zeroes in on the dynamic and fast-growing health sciences sector. Its core objective revolves around generating high current income and ensuring capital appreciation for its investors. This is chiefly achieved through a diversified investment strategy that encompasses a wide array of healthcare companies. These companies span various segments including pharmaceuticals, biotechnology, hospital management, medical devices, and health insurance. By focusing on firms that are at the forefront of medical innovations and advancements, BlackRock Health Sciences Trust aims to tap into the lucrative opportunities presented by the expanding healthcare industry. A unique aspect of the trust is its covered call writing strategy, which plays a pivotal role in enhancing income while providing some level of downside protection. This strategic approach positions the trust as a valuable investment vehicle for those seeking to leverage the growth and dynamism of the healthcare sector. Leveraging the expertise and strategic asset management prowess of BlackRock, its parent organization and a global leader in investment management, BlackRock Health Sciences Trust offers investors expert insights and a disciplined investment approach.
Products and Services
- Investment in Healthcare Companies:
- High Current Income and Capital Appreciation:
- Covered Call Writing Strategy:
At its core, the BlackRock Health Sciences Trust invests in a diversified portfolio of healthcare companies. This encompasses entities across pharmaceuticals, biotechnology, hospital management, medical equipment, and health insurance. The trust aims to select companies that are instrumental in driving medical advancements and innovations, thereby capitalizing on the growth potential within the healthcare sector.
The primary goal of the trust is to generate high current income for its investors, alongside fostering capital appreciation. This dual-focus strategy is designed to offer investors a balanced portfolio with the potential for both steady income and growth, leveraging the steady and sometimes rapid advancements within the health sciences field.
A distinctive feature of the BlackRock Health Sciences Trust is its use of a covered call writing strategy. This strategy involves selling call options on a portion of the portfolio's securities. It serves to enhance the trust’s income potential, offering investors an opportunity to gain additional income from their investments. This strategic approach not only supplements the trust's earnings but also provides some level of protection against the downside, making it an attractive option for those looking to mitigate risk while investing in the high-potential healthcare sector.
